Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy : Clinical, Life-Style, and Genetic Modulators

Show full item record



Permalink

http://hdl.handle.net/10138/174088

Citation

Juhanson , P , Rull , K , Kikas , T , Laivuori , H , Vaas , P , Kajantie , E , Heinonen , S & Laan , M 2016 , ' Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy : Clinical, Life-Style, and Genetic Modulators ' , Journal of Clinical Endocrinology and Metabolism , vol. 101 , no. 12 , pp. 4799-4807 . https://doi.org/10.1210/jc.2016-1873

Title: Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy : Clinical, Life-Style, and Genetic Modulators
Author: Juhanson, Peeter; Rull, Kristiina; Kikas, Triin; Laivuori, Hannele; Vaas, Pille; Kajantie, Eero; Heinonen, Seppo; Laan, Maris
Contributor organization: Institute for Molecular Medicine Finland
Department of Medical and Clinical Genetics
Pregnancy and Genes
Medicum
Clinicum
Department of Obstetrics and Gynecology
Children's Hospital
Lastentautien yksikkö
University of Helsinki
HUS Gynecology and Obstetrics
Date: 2016-12
Language: eng
Number of pages: 9
Belongs to series: Journal of Clinical Endocrinology and Metabolism
ISSN: 0021-972X
DOI: https://doi.org/10.1210/jc.2016-1873
URI: http://hdl.handle.net/10138/174088
Abstract: Context and Objectives: The study represents the first comprehensive analysis of Stanniocalcin-1 (STC1) hormone in human pregnancy, assessing clinical, lifestyle, and genetic determinants of circulating STC1 at term. Design, Setting, and Participants: Participants included women with (n = 50) and without (n = 316) preeclampsia (PE) at delivery, recruited in the REPROgrammed fetal and/or maternal METAbolism (REPROMETA) study (2006-2011, Estonia). Genetic association analysis combined PE cases (n = 597) and controls (n = 623) from the REPROMETA and Finnish Genetics of Preeclampsia Consortium (2008-2011) studies. Main Outcome Measure(s): Maternal postpartum plasma STC1 was measured by ELISA (n = 366) and placental STC1 gene expression by TaqMan quantitative RT-PCR (n = 120). Genotyping was performed using Sequenom MassArray. Results: Significantly higher STC1 plasma level was measured for the PE (median, 1952 pg/mL; 1030-4284 pg/mL) compared with non-PE group (median, 1562 pg/mL; 423-3781 pg/mL; P = 3.7 = 10 = 4, Mann-Whitney U test). Statistical significance was enhanced after adjustment for cofactors (linear regression, P = 1.8 x 10(-6)). STC1 measurements were negatively correlated with maternal smoking. Prepregnancy body mass index had a positive correlation with STC1 only among PE patients (r = 0.45; P =.001). The strongest genetic association with hormone concentrations was detected for STC1 single nucleotide polymorphisms rs3758089 (C allele: minor allele frequency, 5%; linear regression: beta = 249.2 pg/mL; P =.014) and rs12678447 (G allele: minor allele frequency, 7%; beta = 147.0 pg/mL; P =.082). rs12678447 placental genotypes were significantly associated with STC1 gene expression (P =.014). The REPROMETA/Finnish Genetics of Preeclampsia Consortium metaanalysis suggested an increased risk to develop late-onset PE for the rs12678447 G allele carriers (P =.05; odds ratio = 1.38 [0.98 -1.93]). Conclusions: Increased STC1 hormone represents a hallmark of late-onset PE. STC1 gene variants modulate placental gene expression and maternal hormone levels.
Subject: EXPRESSION
LACTATION
GESTATION
PROFILE
KIDNEY
GROWTH
MODEL
MICE
3123 Gynaecology and paediatrics
Peer reviewed: Yes
Rights: cc_by_nc
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
jcem4799.pdf 602.3Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record